74 patents
Page 3 of 4
Utility
Etanercept formulations exhibiting marked reduction in sub-visible particles
2 Nov 20
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture.
Mark Manning, Brian Murphy, Douglas Farrar, Alan Herman
Filed: 7 Jan 15
Utility
Stable aqueous formulations of adalimumab
12 Oct 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 28 Jun 18
Utility
Stable aqueous formulations of adalimumab
28 Sep 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 14 Aug 17
Utility
Stable aqueous formulations of adalimumab
21 Sep 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 17 Jul 17
Utility
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
14 Sep 20
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 15 Jan 20
Utility
Stable aqueous formulations of adalimumab
14 Sep 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 28 Jun 18
Utility
Stable aqueous formulations of adalimumab
14 Sep 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 28 Jun 18
Utility
Etanercept formulations stabilized with xylitol
14 Sep 20
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 24 Feb 19
Utility
Stable Aqueous Formulations of Aflibercept
5 Aug 20
A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.
Jun Liu, Mark Manning, Sekhar R. Kanapuram
Filed: 9 Sep 19
Utility
Stable aqueous formulations of adalimumab
27 Jul 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 31 Oct 18
Utility
Stable aqueous formulations of adalimumab
20 Jul 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 31 Oct 18
Utility
Stable aqueous formulations of adalimumab
20 Jul 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 31 Oct 18
Utility
Stable aqueous formulations of adalimumab
20 Jul 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 31 Oct 18
Utility
Methods for Producing Recombinant Proteins
1 Jul 20
Provided herein are methods of producing a recombinant protein that include: providing a bacterium including a nucleic acid encoding a recombinant protein; and culturing the bacterium in a liquid culture medium including about 0.3 mM to about 300 mM Mg2+ under conditions sufficient for the production and release of the recombinant protein into the culture medium.
Robert Neal Williams
Filed: 4 Dec 19
Utility
Process for Producing, Isolating, and Purifying Modified Recombinant Proteins
1 Jul 20
The invention provides for methods and processes for producing, isolating, and purifying modified proteins.
Stuart Gallant, John Ogez, Charles Olson
Filed: 26 Dec 19
Utility
Stable aqueous formulations of adalimumab
22 Jun 20
The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Robert W. Payne
Filed: 28 Jun 18
Utility
Methods for the Treatment of Nonalcoholic Fatty Liver Disease And/or Lipodystrophy
13 May 20
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARy agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 15 Jan 20
Utility
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
10 Feb 20
The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARγ agonist, INT131 and optionally vitamin E or compositions thereof.
Christos Mantzoros
Filed: 6 Mar 16
Utility
Etanercept formulations stabilized with sodium chloride
2 Dec 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 17 Oct 12
Utility
Etanercept formulations stabilized with meglumine
25 Nov 19
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Mark Manning, Brian Murphy
Filed: 17 Oct 12